NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Metropolis Healthcare has initiated a postal ballot process to seek shareholder approval for a 3:1 bonus share issue. Under this proposal, shareholders will receive three new fully paid-up equity shares of ₹2 each for every one existing share held. The company intends to capitalize a sum not exceeding ₹31.10 crore from its securities premium, general reserves, or retained earnings. The e-voting period for this resolution is scheduled from February 7, 2026, to March 8, 2026, with final results expected by March 10, 2026.
முக்கிய அம்சங்கள்
Proposed bonus issue in the ratio of 3:1 (3 new shares for every 1 existing share)Total capitalization amount from reserves not to exceed ₹31.10 croreRemote e-voting period set for February 7, 2026, to March 8, 2026Record date for eligibility to be determined and announced following shareholder approvalBonus shares will rank pari-passu in all respects with existing equity shares
👀 கவனிக்க வேண்டியவை
Investors should monitor for the announcement of the 'Record Date' as the stock price will undergo a proportional adjustment on the ex-bonus date. While fundamentally value-neutral, the move is expected to improve the stock's liquidity and indicates management's confidence in the company's reserves.
Metropolis Q3FY26: Organic PAT Jumps 52% YoY; Group Revenue Up 26% to ₹406 Cr
Metropolis Healthcare reported a strong Q3FY26 with organic revenue growing 15% YoY to ₹371 Cr and Group revenue (including recent acquisitions) rising 26% to ₹406 Cr. Organic EBITDA margins expanded significantly by 280 bps to 25.0%, driven by operating leverage and productivity gains. The company witnessed robust volume growth with organic patient counts up 9% and test volumes up 8%. Strategic focus on high-value segments like TruHealth (wellness) and Specialty testing, which grew 25% and 16% respectively, continues to drive premiumization and higher realizations.
முக்கிய அம்சங்கள்
Organic PAT surged 52% YoY to ₹48 Cr, while Group PAT grew 63% to ₹51 CrOrganic EBITDA margin improved to 25.0%, up from 22.2% in the previous yearTruHealth (wellness) segment revenue grew 25% YoY, now contributing 19% of total revenueRevenue Per Patient (RPP) increased by 6% YoY to ₹1,116, reflecting a shift toward premium testsNetwork expanded to 219 labs and over 4,800 service points across approximately 750 towns
👀 கவனிக்க வேண்டியவை
Investors should take note of the significant margin expansion and the successful integration of recent acquisitions like Core Diagnostics. The company's ability to drive volume growth while increasing revenue per patient through specialty testing makes it a strong play in the diagnostic sector.
Metropolis Q3FY26: PAT Surges 63% to ₹51 Cr, Revenue Up 26%; 3:1 Bonus Issue Announced
Metropolis Healthcare reported a strong performance for Q3FY26, with revenue growing 26% YoY to ₹406 crore. Profit After Tax (PAT) surged 63% YoY to ₹51 crore (excluding exceptional items), while EBITDA grew 32% to ₹95 crore. The growth was driven by a 14% increase in patient volumes and a significant 35% jump in B2B revenues. Additionally, the Board has approved a 3:1 bonus issue, reflecting management's confidence in the company's long-term growth trajectory.
முக்கிய அம்சங்கள்
Revenue increased by 26% YoY to ₹406 crore, supported by a 14% growth in patient volumes.PAT (excluding exceptional items) grew 63% YoY to ₹51 crore, while EBITDA rose 32% to ₹95 crore.B2B segment outperformed with ~35% YoY growth, while TruHealth and Specialty portfolios grew 37% and 34% respectively.Operational metrics improved with Revenue per Test (RPT) up 11% and Revenue per Patient (RPP) up 10% YoY.The Board approved a 3:1 bonus issue of equity shares to reward shareholders.
👀 கவனிக்க வேண்டியவை
Investors should view these results positively as the company shows strong execution in both B2B and B2C segments with expanding margins. The bonus issue and volume growth in Tier II/III cities suggest a robust outlook for the diagnostic major.
Metropolis Healthcare Announces 3:1 Bonus Issue and Q3 FY26 Results
Metropolis Healthcare has approved a significant 3:1 bonus issue, providing three new equity shares for every one share held by investors. For the quarter ended December 31, 2025, the company reported standalone revenue of ₹334.78 crore and a profit of ₹32.03 crore, showing growth over the previous year's ₹27.40 crore profit. The company is also streamlining operations by transferring its EQAS division to a wholly-owned subsidiary for ₹1.25 crore via a slump sale. Results were slightly impacted by a one-time exceptional charge of ₹7.96 crore related to the new Labour Code provisions.
முக்கிய அம்சங்கள்
Approved a 3:1 bonus issue of equity shares of face value ₹2 each.Standalone revenue from operations grew to ₹334.78 crore in Q3 FY26 from ₹296.88 crore in Q3 FY25.Standalone PAT for the quarter stood at ₹32.03 crore, up 16.9% compared to ₹27.40 crore YoY.Divested EQAS Division to a wholly-owned subsidiary for ₹1.25 crore to optimize business structure.Recognized a non-recurring exceptional expense of ₹7.96 crore due to the implementation of new Labour Codes.
👀 கவனிக்க வேண்டியவை
The 3:1 bonus issue is a positive signal of management's confidence in the company's long-term growth and liquidity. Investors should stay invested while monitoring the impact of recent acquisitions like DAPIC and Scientific Pathology on consolidated margins.
Metropolis Launches Centre of Genomics; Plans Expansion to 500+ Advanced Tests
Metropolis Healthcare has launched its 'Centre of Genomics' to scale precision diagnostics and genomic research in India. The facility is equipped with Illumina’s NovaSeq™ X Series, which can generate over 20,000 whole genomes annually, doubling the throughput of previous systems. Currently offering 220+ validated genomic tests, the company plans to expand this portfolio to over 500 assays within the next two to three years. This strategic move targets high-margin segments like oncology, neurology, and rare diseases while positioning the company for global clinical trial partnerships.
முக்கிய அம்சங்கள்
Launched Centre of Genomics supported by two CAP-accredited labs in Mumbai and Delhi NCR.Deployed Illumina’s NovaSeq™ X Series technology capable of 20,000+ whole genomes per year.Current portfolio of 220+ genomic tests to be expanded to 500+ assays in the next 2-3 years.Focuses on high-impact clinical areas including oncology, reproductive health, and transplant immunology.Positioning as a strategic partner for global pharmaceutical programs and companion diagnostics.
👀 கவனிக்க வேண்டியவை
This expansion into high-end genomics is a margin-accretive move that enhances Metropolis's competitive edge in specialized diagnostics. Investors should watch for improvements in Average Revenue Per Patient (ARPP) as these high-value tests gain traction.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
Metropolis Reports Strong 26% YoY Revenue Growth in Q3FY26 Business Update
Metropolis Healthcare delivered a robust 26% YoY consolidated revenue growth for Q3FY26, driven by wellness and specialty testing. The TruHealth wellness segment grew by 35%, while the specialty segment saw a 33% increase, reflecting a shift towards high-end diagnostics. B2B revenues surged by 37%, significantly aided by the integration of Core Diagnostics and other recent acquisitions. Despite Q3 being a seasonally weak period, the company reported EBITDA margin expansion, showcasing strong operating leverage and successful integration of acquired entities.
முக்கிய அம்சங்கள்
Consolidated revenue grew by approximately 26% YoY, including contributions from recent acquisitions like Core Diagnostics.TruHealth Wellness and Specialty segments recorded strong YoY growth of 35% and 33% respectively.B2B revenue growth stood at 37% YoY, while B2C revenue grew by 18% YoY on a consolidated basis.Standalone EBITDA margins expanded YoY despite the quarter being seasonally weaker for the diagnostic industry.Integration of acquisitions like DAPIC and Scientific Pathology is delivering operational efficiencies and outperforming average margins.
👀 கவனிக்க வேண்டியவை
Investors should view this as a strong performance indicator, particularly the margin expansion and high-growth specialty segments. Monitor the upcoming detailed financial results for specific profit figures and management guidance on sustaining this momentum.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
